netscientific

Differentiated PLC Investment Model Designed for Deeptech

Dr. Ilian Iliev, CEO

Mello2023 Investor Conference

23 May 2023

Disclaimer

This presentation (and any information contained in any oral presentation accompanying it) (Presentation) has been prepared by NetScientific Plc (Company). This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 (FSMA). This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Any person who receives this Presentation should not rely or act upon it. Any person who is in any doubt about this Presentation should consult a person duly authorised for the purposes of FSMA who specialises in the acquisition of shares and other securities.

Whilst the information contained in this Presentation has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as **Information**) and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation. All statements of opinion and/or belief contained in this Presentation and all views expressed represent the directors' own current assessment and interpretation of information available to them as at the date of this Presentation.

This Presentation has not been fully or independently verified and is subject to material updating, revision and further amendment. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.

This Presentation contains certain forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. These forward-looking statements include, but are not limited to, statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, prospects, growth, forecasts, projections, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Therefore, actual results and future events could differ materially from those anticipated in such statements. No representation is made or assurance given that such statements or views are correct or that the objectives of the Company will be achieved. The reader is cautioned not to place reliance on these statements or views and no responsibility is accepted by the Company or any of its shareholders, directors, officers, agents, employees or advisers in respect thereof.

This Presentation does not constitute an offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever.

Neither this Presentation nor any copy of it may be: (a) taken or transmitted into Australia, Canada, Japan, the Republic of Ireland, the Republic of South Africa or the United States of America (each a **Restricted Territory**), their territories or possessions; (b) distributed to any US person (as defined in Regulation S under the United States Securities Act of 1933 (as amended)); or (c) distributed to any individual outside a Restricted Territory who is a resident thereof, in any such case for the purpose of offer for sale or solicitation or invitation to buy or subscribe any securities or in the context where its distribution may be construed as such offer, solicitation or invitation, in any such case except in compliance with any applicable exemption. The distribution of this document in or to persons subject to other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction.

By accepting receipt or attending any delivery of, or electronically accessing, this Presentation, each recipient agrees to be bound by the above limitations and conditions and, in particular represents, warrants and undertakes to the Company that: (i) they will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose; and (ii) they agree to comply with the contents of this notice.

About NetScientific

NetScientific plc (AIM: NSCI) is an investment and commercialisation group with focus on life sciences, sustainability, industrials

- NS acquisition of Deeptech specialist EMV Capital in September 2020 transformed the company from a standstill into a scalable VC business
- Identifying, investing, and building high growth companies in the UK and internationally
- Growing from 8 to 24 companies in 2.5 years; Fair Value increased from £11.8m to £31m end of 2021
- Proactive management of portfolio and value creation
- Capital-light investment approach: cautious use of balance sheet, driving syndicated investments
- A mixture of direct equity stakes and carried interest stakes in portfolio



Effective Board Leadership & Corporate Governance

Dr. Ilian Iliev, CEO

- Founder of EMV Capital – acquired by NetScientific PLC in 2020
- Significant shareholder of NetScientific (15%+)
- Experienced investor, negotiator, strategist & hands-on manager
- IP commercialisation at CambridgeIP; experience in energy, industrials, medtech
- PhD Cambridge University Judge Business School

Ed Hooper, Executive Director and Group General Counsel

- Former Partner of a City headquartered international law firm
- 20+ years experience as a lawyer, specialising in advising on a broad range of transactions, including fundraisings, M&A, IPOs, joint ventures and restructurings, many on an international scale
- Solicitor of the Senior Courts of England and Wales



Dr. Jonathan Robinson,
Interim Non-Executive Chair and Chair of Audit Committee

- Experienced company director, entrepreneur and investor
- Co-founded the publicly quoted Group NBT plc, which ultimately became NetNames Group. Director and CEO of the group
- Previously non-executive director of Nominet
- PhD in Materials Engineering from University of Cape Town

Prof. Stephen Smith, Non-Executive Director, Chair of Remuneration and Nomination Committees

- Senior academic roles in University of Cambridge, Imperial College London and internationally
- Recent Chairman of NHS Trust and NED of other Companies
- Founded GNI Group, Tokyo-listed Cambridge University spin-out

Stephen Crowe, CFO

- Experienced finance leader with 20+ years experience in a wide range of financial institutions from blue chip organisations (AXA) to SMEs (THB Group, R K Carvill & Co. and Towergate Partnership)
- Qualified chartered accountant
- Degree from Auckland University (NZ)

SUPPORTED BY STRONG OPERATIONAL AND INVESTMENT TEAM, VENTURE PARTNERS AND ADVISORS

Growth Strategy Key Levers

- **Proactive management:** Board representation in 13 companies
- **“Capital light” investment:** leveraging NS balance sheet & Plc status for syndicated funding
- **Value Creation:** value creation or fundraising programs with 10 companies
- **Cohort focus approach:** deeper direct stakes alongside advised capital – scope for significant investment returns
- **Service fees:** corporate finance and value creation service fees supporting cost of infrastructure

Executing growth

- **Focus:** value inflection, exit & liquidity events, to realise shareholder returns
- **Scalable model:** continued improvement of infrastructure and processes to deliver performance
- **Internationalisation:** support internationalisation of companies exploit potential and harness synergies

BUILD & REALISE SHAREHOLDER VALUE

Group Portfolio – Diversified Risk and Increased Investment Return Opportunities

netscientific

24 companies in Life Sciences, Deeptech and Sustainability segments

PDS Biotechnology
NASDAQ-listed
EMV CAPITAL
Glycotest
q-bot
Vortex BIOSCIENCES
ventive naturally intelligent ventilation
sofant technologies
Martlet
DName-iT
ProAxsis
PointGrab
SAGETECH MEDICAL
WandaHealth
Recycling Technologies
Quantalx • Neuroscience •
FOx BIOSYSTEMS
EPIBONE
Cytovale
G-Tech Medical
INSIGHT
LONGEVITY BIOTECH™
CETROMED
NIS NANOTECH INDUSTRIAL SOLUTIONS
oncocidia

**Portfolio comprises of equity investments and exposure to companies through carried interest, realisable on exit*

BALANCED PORTFOLIO FOR ENHANCED PERFORMANCE AND RISK MITIGATION

Advantages of Model

- **Capital light investment strategy**: enables NetScientific to support its portfolio companies with a very selective use of its balance sheet
- **Proactive investment approach:** opens up value opportunities, investments on advantageous conditions
- **Value creation services**: selective interventions in portfolio companies – accelerating growth and de-risking
- **Fee-based services:** offsetting the costs of running a VC operation
- **Strong corporate links:** Joint Development Agreements, co-investments, validation
- **Early liquidity:** generating investment returns ahead of full exits, cash supporting operations
- **Routes to exit:** mature portfolio - several portfolio companies with routes to exit
- **Internationalisation:** strong international investor and corporate networks, footprint in US and EU – helping companies internationalise early
- **Driving portfolio synergies:** accelerating growth and creating new opportunities for innovation

2022 Trading Update:
Progress Despite Challenging Market Conditions

- **Continued fair value growth (from £31m at end of 2021):** Reflecting pro-active management, key value creation projects and fund-raisings
- **Portfolio:** Selectively participated in/led 10 investments through both direct and syndicated means, aligning with our capital light model
- **Partial Liquidity:** profitable partial sell-down from a privately held portfolio company – 'proof of concept' demonstrating 'evergreen' potential of model
- **Expanded portfolio of 24 companies** by taking direct stakes in 3 companies on advantageous (non-cash) terms – significant upside potential added
- **Infrastructure:** team growth and model consolidation; EMV Capital increased revenues and covering costs
- **Placement:** NSCI Placing of £1.5m to support strategy implementation
- **Board Changes** to drive growth ambitions, and key strategic hires to expand transactional and portfolio management capabilities

**Final results for the year to 31 December 2022 to be announced soon*

CONTINUED POSITIVE MOMENTUM, SHOWN IN GOOD RESULTS

Active Portfolio Management and Value Creation

netscientific

Concentrating on a “cohort” of companies, taking deeper stakes, with a focus on value creation and investment realisations

Selective new investments that align with our model, offer good value, and can benefit from value creation services

CONTINUED SUPPORT THROUGH SUCCESSIVE STAGES

Deal flow of new opportunities

Acquire stake on advantageous terms	Rebuild/ review business plan and model	Support through value inflection points	Investment readiness	Lead fund-raise	IPO/Exit, Partial liquidity
Recycling Technologies	DName-iT	Glycotest	ProAxsis (a NetScientific portfolio company)	q-bot	PDS Biotechnology
		ventive	Wanda Health (Engaging Telehealth)	Vortex Biosciences	
			PointGrab	Sagetech Medical Equipment	
				sofant technologies	

Portfolio Highlights: Selective Deeper Involvement

netscientific

Vortex BIOSCIENCES

Vortex, US-UK (liquid biopsy, oncology, 30% direct)

- NSCI took 30% stake for a non-cash consideration (on books at £300k cost)
- Multi-year fee-based support helped with turnaround
- EMV Capital-led EIS Investment round
- Now positioned for growth in US, UK, EU in oncology research and liquid biopsy markets
- Dual-based in San Francisco and London



q-bot

Q-Bot, UK (robotics as a service, home retrofit insulation, 17.6% direct, 30.9% under advisory)

- Mature robotics technology company with growing sales in UK retrofit industry
- In 2021 acquired strategic stake in company at attractive valuation – as part of turnaround strategy
- Paid-for management services support + EMV Capital led investments
- Sales more than 2x to c.£4m+
- Driving change, accelerating UK growth, US and EU opportunities

PDS Biotechnology

PDS Biotechnology Corp, NASDAQ:PDSB (Immuno-oncology, c.4.7% share)

- Continued progress with 4 Phase 2 trials with Merck Inc, NCI, MD Anderson, Mayo Clinic
- Launching Phase 3
- In-licensing deal with Merck KGaA
- Strong cash position to progress strategy

Current market cap c.$246m (22 May 23)



…TARGETED COMPANIES WITH POTENTIAL FOR GREATER RETURNS…

Portfolio Highlights: Selective Deeper Involvement

netscientific

Martlet

Martlet Capital Ltd (Cambridge)

- A leading early-stage VC in Cambridge
- 49 portfolio companies in Cambridge high-tech
- EMV Capital supported MBO from Marshall Group in 2021 (alongside SARANAC) – minority stake
- Close links between EMV Capital and Martlet Capital
- Working on follow-on and co-investment structures



Recycling Technologies®

Deeptech Recycling Ltd (30% direct stake)

- Originated and drove strategy to acquire the assets of Recycling Technologies Ltd from the Administrator
- Well-known developer of plastic-waste recycling technology platform
- Earlier in 2022 the company was targeting an AIM IPO with a market capitalisation of £80m+
- Value Creation team working on relaunch of business in a more ‘capital light’ approach



…TARGETED COMPANIES WITH POTENTIAL FOR GREATER RETURNS…

Outlook: NSCI Strategic Objectives FY2023+

netscientific

Progress Sustainable Business Model

- The generation of more fees from EMV Capital
- Selective divestments
- External funding for subsidiaries
- Expand funds practice

Increase the NAV and Fair Value

- Progress portfolio companies through value creation stages
- Third party investment rounds
- Proactive portfolio management

Generate Investment Returns

- Profitable exits of select portfolio companies
- Targeted growth of a curated portfolio

Summary - Q&A

netscientific

Transformed business, a robust investment model

- Maturing portfolio with added potential, drive for exits/liquidity events
- Management commitment and focus, well placed and flexible
- Align underlying (and increasing) asset value with market cap
- Strong fees and deals pipeline for 2023
- Multiple opportunities to grow and realise shareholder returns

Stay tuned for the release of FY2022 Annual Results

Follow-us on Linked-in and website newsletter sign-up

Thank you! Q&A

www.netscientific.net

Impact and Recognition

netscientific



BIOTECH

Merck KGaA hands over IL-12-targeting cancer med to PDS Biotech in $121M deal

Lab-grown bones will save patients from having their own bone harvested if they need a graft

Sofant Technologies signs €7.3 million European Space Agency contract

Guy's and St Thomas' study confirms high capture efficiency of SageTech Medical's solution

PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial

This tiny Q-Bot could save you a fortune on heating bills

The Q-Bot is currently being used by UK councils to insulate homes